MRD & Disease Monitoring

March 17, 2025

MRD Kinetics of Zanubrutinib-Venetoclax-Obinutuzumab in CLL

Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.

February 20, 2025

MRD-Guided Venetoclax Plus Obinutuzumab Therapy for CLL

Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.

January 28, 2025

Undetectable Measurable Residual Disease in CLL / SLL

Undetectable measurable (minimal) residual disease (uMRD) has strong prognostic significance in CLL and may, in the future, guide the duration of therapy.

March 20, 2024

MRD Guided Acalabrutinib, Venetoclax, and Obinutuzumab Therapy for CLL

MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.

February 15, 2024

MRD-Guided Treatment of CLL with Ibrutinib Plus Venetoclax

Measurable residual disease (MRD)-guided treatment of CLL with ibrutinib plus venetoclax significantly increased time in remission.

September 13, 2022

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed MRD as a biomarker to direct treatment duration in a phase 2 clinical trial of

September 1, 2022

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

We discuss the latest results from the GLOW study, a phase 3 clinical trial which compared fixed-duration ibrutinib + venetoclax with chemoimmunotherapy (chlorambucil + obinutuzumab) as a first-line treatment.

September 1, 2022

ASH 2021: High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Various combinations of venetoclax plus other agents such as venetoclax plus rituximab (RVe), venetoclax and obinutuzumab (GVe), or venetoclax plus rituximab plus obinutuzumab (GIVe) provide fixed duration treatment options with high rates of success.

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.